drugset / Trial / NCT01173926

Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes

NCT01173926

Phase 1 Completed 27 enrolled Novo Nordisk A/S
RandomizedCrossoverOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to compare the blood glucose-lowering effect of NN5401 (insulin degludec/insulin aspart, IDegAsp) with NN1250 (insulin degludec, IDeg) and insulin aspart (IAsp) in subjects with type 1 diabetes mellitus.

Timeline

Start
2010-07
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin aspart Protein / enzyme biologic Subcutaneous
Subject insulin degludec Protein / enzyme biologic Subcutaneous
Subject insulin degludec/insulin aspart Unknown Subcutaneous